Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation | Zendy

Pamela L. Lutsey | Zendy; Faye L. Norby | Zendy; Kristine E. Ensrud | Zendy; Richard F. MacLehose | Zendy; Susan J. Diem | Zendy; Lin Y. Chen | Zendy; Álvaro Alonso | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation

Author(s) -

Pamela L. Lutsey,

Faye L. Norby,

Kristine E. Ensrud,

Richard F. MacLehose,

Susan J. Diem,

Lin Y. Chen,

Álvaro Alonso

Publication year - 2019

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2019.5679

Subject(s) - medicine , atrial fibrillation , warfarin , apixaban , rivaroxaban , dabigatran , propensity score matching , stroke (engine) , hip fracture , population , osteoporosis , mechanical engineering , environmental health , engineering

Warfarin is prescribed to patients with atrial fibrillation (AF) for the prevention of cardioembolic complications. Whether warfarin adversely affects bone health is controversial. The availability of alternate direct oral anticoagulant (DOAC) options now make it possible to evaluate the comparative safety of warfarin in association with fracture risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research